• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

2 Minute Medicine Rewind November 24 – December 1, 2013

bys25qthea
December 3, 2013
in Cardiology, Chronic Disease, Gastroenterology, Infectious Disease, Obstetrics, Oncology, Pediatrics, Weekly Rewinds
Reading Time: 4 mins read
RAS mutation linked with survival in metastatic colorectal cancer
Share on FacebookShare on Twitter

Image: PD

In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week.

Exdoxaban versus Warfarin in Patients with Atrial Fibrillation

Factor Xa inhibitors have been shown to be noninferior to warfarin for prevention of venous thromboembolism, and dabigatran has been compared for anticoagulation in patients with non-valvular atrial fibrillation. In this large randomized, double-blind, double-dummy trial 21,105 patients with non-valvular atrial fibrillation were randomized to receive warfarin, low-dose edoxaban, or high-dose edoxaban. The primary outcomes were time to stroke or systemic embolism and drug safety (major bleeding). Both edoxaban groups were noninferior to warfarin, and high-dose edoxaban was more effective in preventing embolic events than warfarin. The rate of stroke or systemic embolism was 1.50% per year in the warfarin group, 1.18% in the high-dose edoxaban group (p<0.0001 for noninferiority, p=0.02 for superiority), and 1.61% in the low-dose edoxaban group (p=0.005 for noninferiority, p=0.44 for superiority). Participants on edoxaban also had significantly less bleeding (high dose 2.75%, low dose 1.61%) than those on warfarin (3.43%, HR 0.80 and 0.47 for high- and low-dose edoxaban, respectively, p<0.0001).

Induced Hypothermia in Severe Bacterial Meningitis: A Randomized Clinical Trial

Induced hypothermia reduces brain injury in conditions with global cerebral hypoxia. No randomized trials have been done assessing the safety and efficacy of induced hypothermia in bacterial meningitis, though experimental studies are promising. Investigators at multiple centers in France randomized 98 comatose adults with bacterial meningitis to receive cooling to 32-34°C for 48 hours or standard care to study the impact on the patient’s Glasgow Outcome Scale score after 3 months. The study was stopped early due to higher mortality at 3 months in the intervention group than the control group (51% vs 31%, RR 1.99, 95% CI 1.05-3.77, p=0.04). Post-hoc analysis showed it would be highly unlikely to find that moderate hypothermia would improve outcomes in patients with bacterial meningitis (probability = 0.023, probability to conclude in favor of futility = 0.977). There was no significant difference in mortality or unfavorable outcome (Glasgow Outcome Score <5) between intravenous or other forms of cooling (p=0.36 and p=0.46 respectively).

RELATED REPORTS

Increased rapid eye movement (REM) sleep is associated with lower risks of several chronic diseases

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

2 Minute Medicine Rewind September 7, 2026

Effect of Thalidomide on Clinical Remission in Children and Adolescents with Refractory Crohn Disease: A Randomized Clinical Trial

Pediatric Crohn’s disease is often more severe and refractory than adult-onset Crohn’s disease, and insufficient disease control can result in delayed development and a need for surgery. In this randomized, double-blind trial, 56 children with refractive Crohn’s disease were randomized to receive low-dose thalidomide or placebo to study the effect on clinical remission, defined as a Pediatric Crohn Disease Activity Index score less than 10, at 8 weeks. A greater proportion of children in the thalidomide group (46%) reached clinical remission compared to the placebo group (11%, RR 4.0, p=0.01) at 8 weeks, though the effect was not significantly different at 4 weeks. Mean remission time was 181.1 weeks in those who achieved remission. This study included children who had previously failed treatment with infliximab and suggests that thalidomide may be used effectively in refractory Crohn’s disease.

Increased Risk of Colorectal Cancer After Obesity Surgery

Bariatric surgery is an increasingly common treatment for obesity, and has positive effects on diabetes and cardiovascular outcomes, but long-term cancer risk is not well-studied, and investigators have observed an unexpected increase in colorectal cancer incidence after such surgery. In this retrospective cohort study, the records of 15,095 Swedish patients who had undergone obesity surgery and 62,016 obese patients who had not had surgery were reviewed for occurrence of colon cancer. The standardized incidence ratio (SIR) in the surgery cohort was 1.60 (95%CI 1.25-2.02), compared to 1.26 in the no surgery cohort. In addition, the risk of colorectal cancer increased with longer follow up in the surgery group (SIR=2.0 at 10 years follow up, p=0.05 for trend), but not in the cohort without obesity surgery (SIR=1.27 at 10 years, p=0.66 for trend). It is unclear why bariatric surgery would increase the risk of colorectal cancer.

Impact of Wait Times on Survival of Women with Uterine Cancer

Delayed surgical treatment is related to decreased survival in many types of cancer, though it has not been studied specifically for uterine cancer, and delayed access to surgery is a problem in many places. Researchers in Ontario conducted a retrospective analysis of 9,417 women diagnosed with uterine cancer from 2000 to 2009 to study the association between wait time between diagnosis and surgery and survival time between surgery and death. Decreased survival was associated with surgery <2 weeks after diagnosis and those who waited longer than 12 weeks for surgery. Compared to women who waited longer than 12 weeks for surgery, those who waited 2-6 or 6-12 weeks had significantly decreased mortality (HR 0.0.79, 95%CI 0.7-0.91 and HR 0.80, 95%CI 0.71-0.91 respectively, p<0.001). Worse survival associated with wait times <2 weeks may be due to the acuity of the patient’s condition necessitating surgery.

By Kathleen Li and David Ouyang

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

Tags: atrial fibrillationBMIcolon cancerCrohn's Diseasehyopthermiaobesitythalidomideuterine cancerwarfarin
Previous Post

Childhood varicella vaccination not linked with greater adult herpes zoster infection

Next Post

Mild hypothermia improves neurological outcome after cardiac arrest [Classics Series]

RelatedReports

Cardiology

Increased rapid eye movement (REM) sleep is associated with lower risks of several chronic diseases

September 23, 2026
Nephrology

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

September 9, 2026
Long-term outcomes for off-pump and on-pump CABG are similar
Weekly Rewinds

2 Minute Medicine Rewind September 7, 2026

September 7, 2026
Increasing maternal BMI linked to higher risk of cerebral palsy
Endocrinology

Newer GLP-1 agents yield substantial weight loss in nondiabetic adults

August 31, 2026
Next Post

Mild hypothermia improves neurological outcome after cardiac arrest [Classics Series]

The SAVE trial: Captopril after acute MI reduces mortality and morbidity [Classics Series]

Assisted conception not associated with increased pediatric cancer risk

Rates of multiple births and multiple embryo IVF procedures have decreased in the past decade

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Nirsevimab (Beyfortus) may reduce severe respiratory syncytial virus infections among infants
  • An artificial intelligence (AI) tool achieved high diagnostic accuracy for the identification and prediction of sepsis
  • Use of long-acting broadly neutralizing antibodies may delay human immunodeficiency virus (HIV) rebound following discontinuation of antiretroviral therapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.